SPY760.18+0.40%QQQ689.22+0.15%BTC/USD69,276.08−2.93%DIA524.53+0.39%GLD355.65+0.21%TLT79.41−0.39%

Ultragenyx Pharmaceutical Inc

RARENASDAQ

Trade with Public

$16.27

-0.43-2.57%

At close: Nov 11, 4:00 PM EST

$16.43

-0.27-1.62%

Pre-Market: 8:44 AM EST

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Ultragenyx Pharmaceutical (RARE) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Ultragenyx Pharmaceutical (RARE) stock.

Analyst Consensus — 22 Analysts

19Buy

3Hold

# Analysts22

Latest Upgrades and Downgrades for Ultragenyx Pharmaceutical Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$32→$22
—	Barclays	Eliana Merle	PT Cut	Overweight	$35→$32
—	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$39→$34
—	TD Cowen	Yaron Werber	PT Raise	Buy	$18→$19
—	Morgan Stanley	Maxwell Skor	PT Raise	Equal-Weight	$20→$22
—	Goldman Sachs	Salveen Richter	PT Cut	Neutral	$19→$17
—	Wells Fargo	Benjamin Burnett	PT Raise	Equal-Weight	$18→$19
—	Wedbush	Laura Chico	PT Cut	Neutral	$25→$22
—	UBS	Joon Lee	Initiate	Neutral	$16
—	Evercore ISI Group	Liisa Bayko	PT Raise	In-Line	$16→$18
—	Barclays	Eliana Merle	PT Raise	Overweight	$32→$35
—	Morgan Stanley	Maxwell Skor	PT Raise	Equal-Weight	$18→$20
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$31→$32
—	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$37→$39
—	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$33→$39
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$28→$31
—	Goldman Sachs	Salveen Richter	PT Cut	Neutral	$28→$19
—	Barclays	Eliana Merle	PT Cut	Overweight	$43→$32
—	Wells Fargo	Benjamin Burnett	Downgrade	Overweight→Equal-Weight	$50→$18
—	JP Morgan	Anupam Rama	Downgrade	Overweight→Neutral	$80→$36

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical (RARE) Stock Price Target 2026

Latest Upgrades and Downgrades for Ultragenyx Pharmaceutical Stock

Ultragenyx Pharmaceutical (RARE) Stock Price Target 2026

Latest Upgrades and Downgrades for Ultragenyx Pharmaceutical Stock

Analyst Ratings News

PRO
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $22

PRO
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34

PRO
TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $19

PRO
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22

PRO
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $22

PRO
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34

PRO
TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $19

PRO
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22

PRO
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical (RARE) Stock Price Target 2026

Latest Upgrades and Downgrades for Ultragenyx Pharmaceutical Stock

Ultragenyx Pharmaceutical (RARE) Stock Price Target 2026

Latest Upgrades and Downgrades for Ultragenyx Pharmaceutical Stock

Analyst Ratings News

PROCitigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $22

PROBarclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32

PROCanaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34

PROTD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $19

PROMorgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22

PROGoldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17

People Also Watch

People Also Watch

Analyst Ratings News

PROCitigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $22

PROBarclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32

PROCanaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34

PROTD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $19

PROMorgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22

PROGoldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17

PRO
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $22

PRO
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34

PRO
TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $19

PRO
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22

PRO
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17

PRO
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $22

PRO
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34

PRO
TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $19

PRO
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22

PRO
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17